US009408904B2

(12) **United States Patent**
Wright et al.

(10) **Patent No.: US 9,408,904 B2**
(45) **Date of Patent: Aug. 9, 2016**

(54) **SCALABLE MANUFACTURING PLATFORM FOR VIRAL VECTOR PURIFICATION AND VIRAL VECTORS SO PURIFIED FOR USE IN GENE THERAPY**

(75) Inventors: **John Fraser Wright**, Princeton, NJ (US); **Guang Qu**, Sicklerville, NJ (US); **Bernd Hauck**, Hamilton, NJ (US); **Katherine A. High**, Merion Station, PA (US)

(73) Assignee: **THE CHILDREN'S HOSPITAL OF PHILADELPHIA**, Philadelphia, PA (US)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.

(21) Appl. No.: **13/561,753**

(22) Filed: **Jul. 30, 2012**

(65) **Prior Publication Data**

US 2013/0072548 A1 Mar. 21, 2013

Related U.S. Application Data

(63) Continuation-in-part of application No. PCT/US2011/022371, filed on Jan. 25, 2011.

(60) Provisional application No. 61/299,184, filed on Jan. 28, 2010.

(51) **Int. Cl.**

C07K 14/005	(2006.01)
A61K 39/235	(2006.01)
C07K 14/015	(2006.01)
C12N 15/35	(2006.01)
C12N 15/864	(2006.01)
A61K 39/23	(2006.01)
A61K 48/00	(2006.01)
C12N 7/00	(2006.01)
C12N 15/86	(2006.01)
C07K 2/00	(2006.01)
C12N 15/64	(2006.01)

(52) **U.S. Cl.**

CPC ***A61K 39/23*** (2013.01); ***A61K 48/0091*** (2013.01); ***C07K 2/00*** (2013.01); ***C12N 7/00*** (2013.01); ***C12N 15/64*** (2013.01); ***C12N 15/86*** (2013.01); ***C12N 15/864*** (2013.01); *C12N 15/8645* (2013.01); *C12N 2750/14011* (2013.01); *C12N 2750/14051* (2013.01); *C12N 2750/14111* (2013.01); *C12N 2750/14143* (2013.01); *C12N 2750/14151* (2013.01)

(58) **Field of Classification Search**

CPC A61K 39/12; A61K 39/235; A61K 39/23; A61K 39/42; C12N 7/00; C12N 15/86; C12N 15/70; C12N 2750/14061; C12N 2750/14122; C12N 2750/14132; C12N 2750/14171; C12N 2750/14334; C12N 2750/14361

See application file for complete search history.

(56) **References Cited**

U.S. PATENT DOCUMENTS

6,093,392	A *	7/2000	High et al.	424/93.2
6,593,123	B1 *	7/2003	Wright et al.	435/239
7,261,544	B2 *	8/2007	Qu et al.	425/239
7,704,721	B2 *	4/2010	Wright et al.	435/239
7,998,734	B2 *	8/2011	High et al.	435/320.1
8,137,948	B2 *	3/2012	Qu et al.	435/239
2002/0127582	A1 *	9/2002	Atkinson et al.	435/6
2003/0207439	A1 *	11/2003	Wright et al.	435/239
2004/0002159	A1 *	1/2004	Xiao et al.	435/457
2004/0102388	A1 *	5/2004	High et al.	514/44
2005/0042740	A1 *	2/2005	Qu et al.	435/239
2006/0035364	A1 *	2/2006	Wright et al.	435/239
2007/0243615	A1 *	10/2007	Qu et al.	435/456
2011/0076744	A1 *	3/2011	Wright et al.	435/239
2012/0135515	A1 *	5/2012	Qu et al.	435/320.1

FOREIGN PATENT DOCUMENTS

WO	2005/118792	12/2005
WO	2008/128251	10/2008

OTHER PUBLICATIONS

Kronenberg S, Böttcher B, von der Lieth CW, Bleker S, Kleinschmidt JA. A conformational change in the adeno-associated virus type 2 capsid leads to the exposure of hidden VP1 N termini. J Virol. May 2005;79(9):5296-303.*

"Protein Concentration and Diafiltration by Tangential Flow Filtration." Technical Brief. Millipore Corp., Jun. 2003.*

Qu G, Bahr-Davidson J, Prado J, Tai A, Cataniag F, McDonnell J, Zhou J, Hauck B, Luna J, Sommer JM, Smith P, Zhou S, Colosi P, High KA, Pierce GF, Wright JF. Separation of adeno-associated virus type 2 empty particles from genome containing vectors by anion-exchange column chromatography. J Virol Methods. Mar. 2007;140(1-2):183-92. Epub Dec. 28, 2006.*

Favaro P, Downey HD, Zhou JS, Wright JF, Hauck B, Mingozzi F, High KA, Arruda VR. Host and vector-dependent effects on the risk of germline transmission of AAV vectors. Mol Ther. Jun. 2009;17(6):1022-30. Epub Mar. 17, 2009.*

Sun J, Hakobyan N, Valentino LA, Feldman BL, Samulski RJ, Monahan PE. Intraarticular factor IX protein or gene replacement protects against development of hemophilic synovitis in the absence of circulating factor IX. Blood. Dec. 1, 2008;112(12):4532-41. Epub Aug. 20, 2008.*

(Continued)

Primary Examiner — Rachel B Gill

(74) *Attorney, Agent, or Firm* — Pillsbury Winthrop Shaw Pittman LLP

(57) **ABSTRACT**

Methods for preparing highly purified AAV vector formulations are provided. The highly pure AAV formulations described herein are superior for clinical use.

21 Claims, 4 Drawing Sheets